Announcement on the Subsidiary's Receipt of the Decision of the Environmental Protection Department Ordering to Stop Production and Remediation
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2018-020
Bond Abbreviation: 13 Jianfeng 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement
of the Company's Board of Directors and all directors guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents
Recently, Anhui Xinbeika Chemical Co., Ltd. (hereinafter referred to as "Anhui Beika"), a subsidiary of the company, received the Dongzhi County Environmental Protection Bureau's "Decision on Ordering Suspension of Production and Rectification" (
Donghuan Zit [2018] No. 04), the main contents are hereby announced as follows:1. the contents of the "Decision on Ordering to Stop Production and Rectification"
(I) Investigation and Findings of Environmental Violations
After investigation by our bureau, it is found that your company has implemented the following environmental violations: "Your company's annual output of 500
tons of acetamiprid is in production, and the valve of the gas outlet pipeline of the activated carbon adsorption tank of the waste gas treatment facility in the 201 workshop is closed, the waste gas in the tank overflows from the outlet of the sewage pipe and the inlet and outlet of activated carbon replacement, etc., and the smell on site is heavy." The above facts ofare based on evidence such as the on-site (survey) record, investigation and inquiry record, on-site photos and so on on June 22, 2018
by our bureau.The above actions of your company violate the provisions of Article 20, paragraph 2, of the the People's Republic of China Air Pollution Prevention and Control Law.
The basis and type of the (II)'s decision to suspend production for rectification
According to Item (III) of Paragraph 1 of Article 99 of the the People's Republic of China Air Pollution Prevention and Control Law, and Item (I) of Article 6 of the Measures for the Implementation of Restrictions on Production and Suspension of Production by Environmental Protection Authorities, our bureau has decided to order your company to implement suspension of production for rectification.
Implementation method and deadline for (III) shutdown rectification
1
, your company shall immediately stop production from the date of receipt of this decision, and take corrective measures to formulate and implement the rectification plan.2
. Your company shall report the rectification plan to our bureau for the record and make it public within 15 working days after receiving this decision. The rectification plan shall determine the corrective measures, the progress of the project, the guarantee of funds and the responsible personnel.3
. After your company completes the rectification task, it shall report the completion of the rectification task and the public disclosure of the rectification information to our bureau for the record within 15 working days.4
. Your company shall not have any illegal pollutant discharge during the rectification period, and shall not resume production without reporting the completion of the rectification task to our bureau for the record.The period of suspension of production for rectification is from the date of service of this decision to the date of cancellation of the suspension of production for rectification.
Our bureau will supervise your unit after the implementation of the shutdown rectification, and conduct follow-up inspection after the shutdown rectification is lifted. If your company refuses to carry out rectification as required or commits illegal acts after resuming production, our bureau will impose administrative penalties or administrative treatment in accordance with the law according to your company's illegal circumstances and environmental consequences.
Ways and Time Limit for (IV) to Apply for Administrative Reconsideration or File Administrative Litigation
If your company does not accept this decision, it may apply for administrative reconsideration to Chizhou Municipal Environmental Protection Bureau or Dongzhi County People's Government within 60 days from the date of receipt of this decision in accordance with the provisions of Article 9 of the the People's Republic of China Administrative Reconsideration Law, an administrative lawsuit may also be brought to the people's Court of Dongzhi County within six months from the date of receipt of this decision in accordance with Article 46 of the the People's Republic of China Administrative procedure Law. If an application for administrative reconsideration or an administrative lawsuit is filed, the implementation of this decision shall not be suspended.
If you do not apply for administrative reconsideration, file an administrative lawsuit, or perform this decision within the time limit, our bureau will apply to the people's court for enforcement in accordance with the law.
2. Rectification Measures
Company attached great importance to the above decision and immediately requested Anhui Beika to actively cooperate with the environmental protection department in inspection and stop illegal acts. The specific measures are as follows:
1
. In response to the incident, the company instructed Jianfeng Pharmaceutical to immediately set up an environmental protection incident emergency working group to investigate the incident and supervise the rectification; at the same time, arrange the company's production enterprises to conduct a comprehensive environmental self-examination to prevent the occurrence of similar incidents.2
, prepare a rectification plan and arrange special funds to further upgrade the existing waste gas treatment system in Beika, Anhui Province.
3. During the period of shutdown and rectification, Anhui North Carolina will be arranged to carry out annual routine equipment maintenance to ensure the normal operation of production facilities after resumption of production.
Anhui North Carolina will complete the rectification as soon as possible and report the completion of the rectification to the Environmental Protection Bureau, so as to resume normal production as soon as possible.Impact of 3. on the Company
2018
In January and August, the board of directors of the company approved that the subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. acquired 55% of the equity of Shanghai Beika Pharmaceutical Technology Co., Ltd. by acquiring shares and increasing capital. Anhui Beika is a wholly-owned subsidiary of Shanghai Beika Pharmaceutical Technology Co., Ltd. In May 2018, the industrial and commercial change registration and handover procedures for the investment were completed. In accordance with the "Application Guide to Enterprise Accounting Standards No. 20-Business Combinations", the Company has included Shanghai Beika Pharmaceutical Technology Co., Ltd. and its subsidiaries in the scope of the Company's consolidation since June 2018.At the end of 2017
, the company's total assets were 41.76 .1 billion yuan, and the net assets attributable to the owners of the parent company were 2.627 billion yuan. In 2017, the company realized operating income of 2.827 billion yuan and realized net profit attributable to the owners of the parent company. 0.348 billion yuan. At the end of 2017, Anhui North Card's total assets were 0.047 billion yuan and net assets were 0.012 billion yuan. Anhui North Card's annual operating income in 2017 was 0.046 billion yuan and net profit was -0.008 billion yuan. Anhui North Card's total assets were about 1.13 of the company's total assets and its operating income was about 1.63 of the company's operating income. Anhui North Card has a small impact on the Company's overall operating income and efficiency.
The company will strictly follow the "Shanghai Stock Exchange Stock Listing Rules" and other relevant requirements to do a good job of information disclosure in a timely manner. Please invest rationally and pay attention to investment risks.This is to announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
July 5, 2018
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05